The failure of endothelin antagonists to show benefit in heart failure cannot be understood until all the clinical trials are fully published
- CHF, chronic heart failure
- EARTH, Endothelin A Receptor Antagonist Trial in Heart Failure
- HEAT, Haemodynamic and Neurohumoral Effects of Selective Endothelin A Receptor Blockade in Chronic Heart Failure
- NYHA, New York Heart Association
Statistics from Altmetric.com
Competing interests: NFK is a British Heart Foundation Junior Research Fellow (FS/03/006/15108) and has received grants to attend conferences from Merck, Pfizer and Sanofi. DJW has, in the past, advised Abbott, Actelion, Roche and Bristol-Myers Squibb on the development of ET antagonists, and has undertaken clinical studies using ET antagonists with Astra-Zeneca, Bristol-Myers Squibb, Encysive, Takeda and Vanguard. NFK and DJW have received donations of ET antagonists from Abbott Pharmaceuticals for use in their preclinical research.